A Phase 1 Study of UB-VV500 With Rapamycin in Relapsed/Refractory Multiple Myeloma
Trial statusNot yet recruiting
Trial phasePhase 1
Trial typeInterventional
Biological sexAll
Age18+
SponsorUmoja Biopharma
About this trial
This study is a Phase 1 dose-finding and dose-confirmation study to evaluate the safety and antitumor activity of UB-VV500. The study will enroll patients with relapsed/refractory multiple myeloma.
Eligibility criteria
Qualifiers
18 years or older
Provides voluntary written informed consent
Relapsed or refractory multiple myeloma (MM) following treatment with a proteasome inhibitor, an immunomodulatory drug, and an anti-CD38 antibody
Measurable disease following completion of most recent anticancer therapy
Disqualifiers
Plasma cell leukemia, Waldenstrom's macroglobulinemia, POEMS syndrome, or primary AL amyloidosis
Solitary plasmacytomas without evidence of systemic disease
Women who are pregnant or breastfeeding
Current isolated central nervous system (CNS) involvement
Trial design
Treatments tested in this trial
- UB-VV500
- Rapamycin (sirolimus)
Treatment groups
100 Participants
are divided into 2 treatment groupsLocations
Sponsors and collaborators
Source ClinicalTrials.gov